Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Botanix Pharmaceuticals Limited ( (AU:BOT) ) has issued an update.
Botanix Pharmaceuticals Limited announced the quotation of 9,333,334 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its market presence and provide additional liquidity for its stakeholders, potentially strengthening its financial position and operational capabilities.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development and commercialization of dermatology and antimicrobial products. The company is known for leveraging its proprietary drug delivery technology to enhance the treatment of skin diseases and infections.
Average Trading Volume: 14,771,893
Technical Sentiment Signal: Sell
Current Market Cap: A$323.6M
For an in-depth examination of BOT stock, go to TipRanks’ Overview page.